{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:03Z","timestamp":1791475323048,"version":"4.3.4"},"reference-count":65,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>\n              The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of targeted agents in patients with advanced cancer and genomic alterations. Results of five cohorts of patients with\n              <jats:italic toggle=\"yes\">BRCA1\/2<\/jats:italic>\n              -mutated solid tumors treated with olaparib are reported: breast cancer (BC), biliary tract cancer (BTC), lung cancer (LC), uterine cancer (UC), and other solid tumors (histology-pooled [HP]).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Eligible patients had advanced tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as complete or partial response or stable disease (SD) of at least 16-weeks duration. For histology-specific cohorts, Simon two-stage design is based on a null DC rate of 15% versus 35% (power = 0.85; \u03b1 = .10). Cohorts that were closed before achieving the planned stage II sample size were analyzed using a one-sided exact binomial test. For the HP cohort, the hypothesized null DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was &gt;15%. Secondary end points were objective response, progression-free survival, overall survival, duration of response or SD, and safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Patients with BC (n = 28), BTC (n = 19), LC (n = 25), UC (n = 15), or other advanced cancers (n = 32) with\n              <jats:italic toggle=\"yes\">BRCA1\/2<\/jats:italic>\n              alterations were enrolled. The DC rates with one-sided 90% CI were 69% (55-100,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt; .001), 50% (32-100,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .0008), 41% (26-100,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .0025), 47% (28-100,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .0036), and 41% (29-100), respectively. The null hypothesized 15% DC rate was rejected for all cohorts. Thirty-six of 119 patients experienced treatment-related grade 3-4 adverse events (AEs) or serious AEs.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>\n              Olaparib met prespecified criteria to declare a signal of activity in patients with various advanced\n              <jats:italic toggle=\"yes\">BRCA1\/2<\/jats:italic>\n              -altered solid tumors.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/po-25-00649","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:59:10Z","timestamp":1760644750000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Olaparib in Patients With Solid Tumors With\n            <i>BRCA1\/2<\/i>\n            Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study"],"prefix":"10.1200","clinical-trial-number":[{"clinical-trial-number":"nct02693535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tareq","family":"Al Baghdadi","sequence":"first","affiliation":[{"name":"Michigan Cancer Research Consortium, IHA Hematology Oncology, Ypsilanti, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rothe","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-6742","authenticated-orcid":false,"given":"Pam K.","family":"Mangat","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-0333","authenticated-orcid":true,"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana V.","family":"Crysler","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Comprehensive Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-7743","authenticated-orcid":true,"given":"Kathryn F.","family":"Mileham","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Catherine","family":"Farrington","sequence":"additional","affiliation":[{"name":"City of Hope Chicago, Zion, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamidele","family":"Adesunloye","sequence":"additional","affiliation":[{"name":"City of Hope Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Dublis","sequence":"additional","affiliation":[{"name":"University of Michigan Health-West, Wyoming, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8613-1890","authenticated-orcid":true,"given":"Igor","family":"Astsaturov","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen J.","family":"Calfa","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-7285","authenticated-orcid":true,"given":"Jonathan","family":"Bleeker","sequence":"additional","affiliation":[{"name":"Sanford Health, Sioux Falls, SD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0799-4920","authenticated-orcid":true,"given":"Maya","family":"Khalil","sequence":"additional","affiliation":[{"name":"O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-9924","authenticated-orcid":true,"given":"Ramya","family":"Thota","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare, Murray, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5033-3071","authenticated-orcid":true,"given":"Timothy L.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute, Fairfax, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-4725","authenticated-orcid":true,"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[{"name":"Emory University Winship Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Gold","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8115-9328","authenticated-orcid":true,"given":"Navid","family":"Hafez","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari D.","family":"Baron","sequence":"additional","affiliation":[{"name":"California Pacific Medical Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":true,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evthokia","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2545-3570","authenticated-orcid":true,"given":"Alissa S.","family":"Marr","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-025X","authenticated-orcid":true,"given":"Jens","family":"Rueter","sequence":"additional","affiliation":[{"name":"Jackson Laboratory-Maine Cancer Genomics Initiative, Bar Harbor, ME"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-2471","authenticated-orcid":true,"given":"Bernard","family":"Tawfik","sequence":"additional","affiliation":[{"name":"University of New Mexico Comprehensive Cancer Center, Albuquerque, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-9484","authenticated-orcid":true,"given":"Dominique C.","family":"Hinshaw","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-4369","authenticated-orcid":true,"given":"Abigail","family":"Gregory","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-0419","authenticated-orcid":true,"given":"Gina N.","family":"Grantham","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":true,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-4303","authenticated-orcid":true,"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_12_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206678"},{"key":"e_1_3_12_3_2","article-title":"Biallelic BRCA loss and homologous recombination deficiency in nonbreast\/ovarian tumors in germline BRCA1\/2 carriers","author":"Wineland D","unstructured":"Wineland D, Le AN, Hausler R, et al: Biallelic BRCA loss and homologous recombination deficiency in nonbreast\/ovarian tumors in germline BRCA1\/2 carriers. JCO Precis Oncol 10.1200\/PO.23.00036","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02112"},{"key":"e_1_3_12_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgs132"},{"key":"e_1_3_12_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(00)89089-1"},{"key":"e_1_3_12_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_3_12_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz192"},{"key":"e_1_3_12_9_2","first-page":"11275","article-title":"The tumor therapy landscape of synthetic lethality","volume":"12","author":"Zhang B","year":"2021","unstructured":"Zhang B, Tang C, Yao Y, et al: The tumor therapy landscape of synthetic lethality. Nat Commun 12:11275, 2021","journal-title":"Nat Commun"},{"key":"e_1_3_12_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.02.014"},{"key":"e_1_3_12_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldp005"},{"key":"e_1_3_12_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00680-2"},{"key":"e_1_3_12_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214676"},{"key":"e_1_3_12_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"e_1_3_12_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00003"},{"key":"e_1_3_12_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01035"},{"key":"e_1_3_12_17_2","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","author":"Shroff RT","unstructured":"Shroff RT, Hendifar A, McWilliams RR, et al: Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol 10.1200\/PO.17.00316","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0887"},{"key":"e_1_3_12_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361"},{"key":"e_1_3_12_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_3_12_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01604"},{"key":"e_1_3_12_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00339"},{"key":"e_1_3_12_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"e_1_3_12_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_12_25_2","article-title":"Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00240","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_26_2","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study","author":"Yang ES","unstructured":"Yang ES, Halabi S, Rothe M, et al: Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00505","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_27_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21870"},{"key":"e_1_3_12_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1104"},{"key":"e_1_3_12_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2728"},{"key":"e_1_3_12_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102041"},{"key":"e_1_3_12_31_2","article-title":"Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry study","author":"Srkalovic G","unstructured":"Srkalovic G, Rothe M, Mangat PK, et al: Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.24.00026","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9024"},{"key":"e_1_3_12_33_2","article-title":"Rationale and design of the targeted agent and profiling utilization registry study","author":"Mangat PK","unstructured":"Mangat PK, Halabi S, Bruinooge SS, et al: Rationale and design of the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.18.00122","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_34_2","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Baghdadi TA","unstructured":"Baghdadi TA, Halabi S, Garrett-Mayer E, et al: Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.19.00124","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_35_2","article-title":"Palbociclib in patients with non\u2013small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Ahn ER","unstructured":"Ahn ER, Mangat PK, Garrett-Mayer E, et al: Palbociclib in patients with non\u2013small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.20.00037","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00752-8"},{"key":"e_1_3_12_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00753-7"},{"key":"e_1_3_12_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02923"},{"key":"e_1_3_12_39_2","article-title":"Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Klute KA","unstructured":"Klute KA, Rothe M, Garrett-Mayer E, et al: Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.22.00191","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_40_2","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study","author":"Gupta R","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, et al: Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR study. JCO Precis Oncol 10.1200\/PO.22.00306","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_12_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0435-8"},{"key":"e_1_3_12_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02078"},{"key":"e_1_3_12_44_2","article-title":"Regorafenib in patients with solid tumors with BRAF alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Sahai V","unstructured":"Sahai V, Rothe M, Mangat PK, et al: Regorafenib in patients with solid tumors with BRAF alterations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00527","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_45_2","article-title":"Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry study","author":"Calfa CJ","unstructured":"Calfa CJ, Rothe M, Mangat PK, et al: Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00513","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_46_2","article-title":"Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study","author":"Rohatgi N","unstructured":"Rohatgi N, Rothe M, Mangat PK, et al: Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 10.1200\/PO.23.00279","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_3_12_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215"},{"key":"e_1_3_12_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02151"},{"key":"e_1_3_12_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07165-x"},{"key":"e_1_3_12_51_2","article-title":"Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer","author":"Taza F","unstructured":"Taza F, Holler AE, Fu W, et al: Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer. JCO Precis Oncol 10.1200\/PO.21.00070","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06948-5"},{"key":"e_1_3_12_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60892-6"},{"key":"e_1_3_12_54_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.718871"},{"key":"e_1_3_12_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1382-1"},{"key":"e_1_3_12_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35707"},{"key":"e_1_3_12_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2019.102668"},{"key":"e_1_3_12_58_2","article-title":"Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity","author":"Sokol ES","unstructured":"Sokol ES, Pavlick D, Khiabanian H, et al: Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO Precis Oncol 10.1200\/PO.19.00345","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19406-4"},{"key":"e_1_3_12_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.21"},{"key":"e_1_3_12_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02311-0"},{"key":"e_1_3_12_62_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5218"},{"key":"e_1_3_12_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00369-2"},{"key":"e_1_3_12_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048"},{"key":"e_1_3_12_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1029"},{"key":"e_1_3_12_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3369"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-00649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:59:16Z","timestamp":1760644756000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-00649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1200\/PO-25-00649"],"URL":"https:\/\/doi.org\/10.1200\/po-25-00649","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500649"}}